Positive Phase III results for Indivior's RBP-7000 in schizophrenia

5 May 2015
shaun-thaxter-big

UK-based Indivior (LSE: INDV) today released encouraging top-line results from its Phase III clinical trial of RBP-7000, an investigational drug in development for the treatment of schizophrenia.

Indivior was formed late last year as a result of a demerger of the pharmaceutical business of consumer goods giant Reckitt Benckiser Group (LSE: RB).

In this pivotal study, both doses of RBP-7000 tested, 90mg and 120mg administered once-monthly, met the primary endpoint with statistically- and clinically-significant reductions in the symptoms of acute schizophrenia over an eight-week treatment period. Symptom reduction was measured using the change from baseline to end of treatment in the total Positive and Negative Syndrome Scale (PANSS) scores. RBP-7000 also met the key secondary endpoint with statistically significant improvements in the Clinical Global Impression-Severity of Illness (CGI-S) scale compared with placebo over the eight-week treatment period using change from baseline to end of treatment.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical